Director Li Wang resigns from Park Ha Biological (BYAH) board

Rhea-AI Filing Summary

Park Ha Biological Technology Co., Ltd. reported that Li Wang resigned as a director of the company, effective March 16, 2026. The company states that her resignation was not due to any disagreement with its operations, policies, or procedures.

The report is signed by Chief Executive Officer and Chairperson Xiaoqiu Zhang, indicating the change has been formally approved and acknowledged at the highest leadership level.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-42453

Park Ha Biological Technology Co., Ltd.

901, Building C, Phase 2

Wuxi International Life Science Innovation Campus
196 Jinghui East Road

Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000

+86 400 012 7562

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒        Form 40-F ☐

On March 16, 2026, Ms. Li Wang tendered her resignation as a director of Park Ha Biological Technology Co., Ltd. (the “Company”), effective March 16, 2026. Ms. Li Wang’s resignation was not a result of any disagreement with the Company’s operations, policies or procedures.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Park Ha Biological Technology Co., Ltd.
Date: March 16, 2026	By:	/s/ Xiaoqiu Zhang
	Name:	Xiaoqiu Zhang
	Title:	Chief Executive Officer, Chairperson of the Board of Directors

2

FAQ

What board change did Park Ha Biological Technology Co., Ltd. (BYAH) report in this 6-K?

Park Ha Biological Technology Co., Ltd. reported that director Li Wang resigned from the board, effective March 16, 2026. This filing formally records the leadership change for investors and regulators but does not indicate any operational or financial issues driving the resignation.

Did Li Wang resign from Park Ha Biological Technology (BYAH) due to disagreements with the company?

No, the company states that Li Wang’s resignation was not the result of any disagreement with its operations, policies, or procedures. This language signals the departure is portrayed as non-contentious and not tied to a disclosed corporate dispute or governance conflict.

When did Li Wang’s resignation from Park Ha Biological Technology (BYAH) become effective?

Li Wang’s resignation as a director of Park Ha Biological Technology Co., Ltd. became effective on March 16, 2026. The same date is used both for the resignation’s effectiveness and for the company’s formal signing of the report documenting this board change.

Who signed the Park Ha Biological Technology (BYAH) 6-K reporting Li Wang’s resignation?

The 6-K is signed by Xiaoqiu Zhang, who serves as Chief Executive Officer and Chairperson of the Board of Directors. This confirms that the company’s top executive and board leader has authorized and acknowledged the disclosure of Li Wang’s resignation.

Does the Park Ha Biological Technology (BYAH) 6-K mention any impact on company policies or operations?

The 6-K explicitly states that Li Wang’s resignation was not due to disagreements with the company’s operations, policies, or procedures. It does not describe any changes to those areas, focusing solely on documenting the director’s departure from the board.

What type of SEC report did Park Ha Biological Technology (BYAH) use to disclose Li Wang’s resignation?

The company used a Form 6-K, which is a report for foreign private issuers to disclose material information. This filing records Li Wang’s resignation as a director and confirms there were no stated disagreements underlying her decision to leave the board.